World Health Organization Sounds Alert Over Critical Scarcity of Weight-Loss Jabs
Under one in 10 people eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, caution the World Health Organization as it releases its initial recommendations on the medications.
Given over a billion individuals worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs.
Based on estimates, more than two billion are projected to be obese by 2030 without intervention.
"The new guidelines acknowledges that excess weight is a chronic disease that can be treated with comprehensive and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major obstacles to widespread access to the jabs that can help people shift considerable body mass, says the body.
Weight-Loss Drug Shortage
Even in the current most favorable case, the manufacturing of such drugs might only reach about 100 million people – less than 10% of those who need them, according to the health organization.
The recommendation calls on governments and firms to expand access, through approaches like voluntary licensing.
A patent on semaglutide – the main component of a leading brand – is due to expire in multiple countries in 2026.
The Way Weight-Loss Drugs Operate
The injections mimick a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so users consume fewer calories.
Individuals typically see weight reduction in the initial weeks of beginning the weekly injections.
Studies suggests users may put most of the weight back on within a year of halting the drug, as their normal appetite come back.
To be above a healthy weight increases your likelihood for experiencing medical conditions, like diabetes, heart disease, brain attack, and certain cancers.
Excess weight concerns people in all nations and was linked to millions of fatalities worldwide in 2024, according to the WHO.
